An Update on Lisaftoclax for CLL - Dr. Nicole Lamanna and Dr. Matthew Davids

34 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Lisaftoclax was well-tolerated and active in patients with CLL/SLL, and the combination of lisaftoclax plus acalabrutinib is effective.

Dr. Matthew Davids from Dana-Farber Cancer Institute and colleagues presented the results at the American Society for Hematology (ASH) Annual Meeting 2024.

Read the full article on CLL Society's website at: https://cllsociety.org/2025/08/an-update-on-lisaftoclax-for-cll/
__________________________________________________________________________________________
CLL Society Website: https://cllsociety.org/
Facebook: https://www.facebook.com/CLLsociety
Twitter: https://twitter.com/CllSociety
LinkedIn: https://www.linkedin.com/company/cll-society/
Categoria
Oncology
Commenta per primo questo video.

Prossimo